Compare DLX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLX | PHAR |
|---|---|---|
| Founded | 1915 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1994 | 2020 |
| Metric | DLX | PHAR |
|---|---|---|
| Price | $27.77 | $16.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $23.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 529.9K | 31.0K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.21% | N/A |
| EPS Growth | ★ 52.54 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $2,133,200,000.00 | N/A |
| Revenue This Year | $1.40 | $27.75 |
| Revenue Next Year | $1.66 | $9.39 |
| P/E Ratio | ★ $15.83 | $3,041.22 |
| Revenue Growth | ★ 0.54 | N/A |
| 52 Week Low | $13.61 | $7.50 |
| 52 Week High | $28.60 | $21.34 |
| Indicator | DLX | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 59.76 | 44.14 |
| Support Level | $18.25 | $16.35 |
| Resistance Level | $28.60 | $17.65 |
| Average True Range (ATR) | 0.88 | 0.57 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 75.77 | 50.44 |
Deluxe Corp is principally a payments and data company. Its reportable segments are: Merchant Services, B2B Payments, Data Solutions, and Print. Maximum revenue is derived from its Print segment, which provides printed personal and business checks, business essentials, as well as branded promotional, print, apparel, and digital storefront solutions. The Merchant Services segment provides electronic credit and debit card authorization, payment systems, and processing services. The B2B segment offers treasury management solutions, integrated accounts payable disbursements, and fraud and security services, and the Data Solutions segment offers data, analytics, and marketing services, as well as financial institution profitability reporting and business incorporation services.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.